October 23rd 2024
Routine screening revealed high financial toxicity and unmet social needs among adolescent and young adults with cancer.
October 11th 2024
MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.
October 8th 2024
The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.
October 6th 2024
Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.
October 2nd 2024
The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.
September 27th 2024
Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.
September 26th 2024
Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma
September 24th 2024
Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.
September 16th 2024
In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.
Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.
September 13th 2024
Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.
Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.
September 11th 2024
Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.
September 9th 2024
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.
September 6th 2024
The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.
Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
July 11th 2024
Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.
June 28th 2024
HRQOL data from the CheckMate 8HW trial may support the use of nivolumab and ipilimumab as first-line treatment for patients with MSI-H or dMMR metastatic colorectal cancer.